Targeting poly(ADP-ribose)polymerase1 in neurological diseases: A promising trove for new pharmacological interventions to enter clinical translation-Reference-Cited by-同舟云学术

Targeting poly(ADP-ribose)polymerase1 in neurological diseases: A promising trove for new pharmacological interventions to enter clinical translation

Published:2014-10 Issue: Volume:76 Page:70-81
ISSN:0197-0186
Container-title:Neurochemistry International
language:en
Short-container-title:Neurochemistry International

Author:

Sriram Chandra Shekhar,Jangra Ashok,Kasala Eshvendar Reddy,Bodduluru Lakshmi Narendra,Bezbaruah Babul Kumar

Publisher

Elsevier BV

Subject

Cell Biology,Cellular and Molecular Neuroscience

Reference189 articles.

1. Protective effects of P34, a novel, potent inhibitor of poly (ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke;Abdelkarim;Int. J. Mol. Med.,2001

2. A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response;Adamson;Nat. Cell Biol.,2012

3. NAD+ depletion is necessary and sufficient for poly(ADP-ribose)polymerase-1-mediated neuronal death;Alano;J. Neurosci.,2010

4. The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks;Ali;Nat. Struct. Mol. Biol.,2012

5. Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites;Altmeyer;Nucleic Acids Res.,2009

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Veliparib exerts protective effects in intracerebral hemorrhage mice by inhibiting the inflammatory response and accelerating hematoma resolution;Brain Research;2024-09

2. Elucidating the Therapeutic Utility of Olaparib in Sulfatide-Induced Human Astrocyte Toxicity and Neuroinflammation;Journal of Neuroimmune Pharmacology;2023-11-04

3. Olaparib Attenuates Demyelination and Neuroinflammation in an Organotypic Slice Culture Model of Metachromatic Leukodystrophy;Neurotherapeutics;2023-09

4. Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases;Cancers;2022-01-29

5. Human equivalent dose of oral 4-aminopyridine differentiates nerve crush injury from transection injury and improves post-injury function in mice;Neural Regeneration Research;2020